SCHEMBL40167

SCHEMBL40167

C[C](C)CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL4870551 0.72
Ethane SCHEMBL27801430 0.72
SCHEMBL8522991 0.71
SCHEMBL22063 0.71
SCHEMBL15938 0.71
SCHEMBL67016 0.71
SCHEMBL3398357 0.71
SCHEMBL3398355 0.71
SCHEMBL19043 0.67
SCHEMBL359514 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 5405 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4392032-A1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR FOR THE TREATMENT OR PREVENTION OF RENAL CYSTIC DISEASE AND CARDIORENAL SYNDROME Arena Pharmaceuticals, Inc. (US) 2024-07-03 EP claimed
WO-2024114814-A1 JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS ONQUALITY PHARMACEUTICALS CHINA LTD (CN) 2024-06-06 WO claimed
US-11987588-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2024-05-21 US claimed
CN-118044048-A Electrochemical device and electronic device 宁德新能源科技有限公司 2024-05-14 CN claimed
WO-2024083257-A1 SOS1 PROTEIN DEGRADATION AGENT AND USE THEREOF 上海领泰生物医药科技有限公司 2024-04-25 WO claimed
US-11958923-B2 Compositions with high refractive index and abbe number Johnson & Johnson Surgical Vision, Inc. (US) 2024-04-16 US claimed
EP-3658539-B1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS AG (CH) 2024-02-21 EP claimed
CN-111094242-B Compounds and compositions for treating disorders associated with NLRP activity 诺华股份有限公司 2024-02-09 CN claimed
WO-2024028169-A1 NOVEL SPECIFICALLY SUBSTITUTED THIOPHENOLIC COMPOUNDS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-02-08 WO claimed
WO-2024003259-A1 TEAD INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-01-04 WO claimed
US-4402974-A WITH CARBOXY, OXY, CARBO-AMINE AMERICAN HOSPITAL SUPPLY CORPORATION (US) 1983-09-06 US claimed
EP-0082873-A1 COMPOSITIONS FOR TREATING GLAUCOMA. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-07-06 EP claimed
EP-0081580-A1 COMPOSITIONS FOR TREATING GLAUCOMA. AMERICAN HOSPITAL SUPPLY CORP (US) 1983-06-22 EP claimed
WO-1983000043-A1 COMPOSITIONS FOR TREATING GLAUCOMA AMERICAN HOSPITAL SUPPLY CORP (US) 1983-01-06 WO claimed
WO-1983000014-A1 COMPOSITIONS FOR TREATING GLAUCOMA AMERICAN HOSPITAL SUPPLY CORP (US) 1983-01-06 WO claimed
US-RE29829-E Insect repellent compositions and process having an N-substituted hydroxyalkyl amine as an active ingredient SCM CORPORATION (US) 1978-11-07 US claimed
US-4078146-A TREATMENT OF CARDIO-VASCULAR DISORDERS AKTIEBOLAGET HASSLE (SW) 1978-03-07 US claimed
US-4035420-A CARDIOVASCULAR DISORDERS AKTIEBOLAGET HASSLE (SW) 1977-07-12 US claimed
US-4013787-A CATIONIC POLYMERS SOCIETE ANONYME DITE: L'OREAL (FR) 1977-03-22 US claimed
US-3975541-A Insect repellent compositions having an N-substituted hydroxyalkyl amine as an active ingredient SCM CORPORATION (US) 1976-08-17 US claimed